Processing

Please wait...

Settings

Settings

1. SG11201610036P - ANTIBODIES DIRECTED AGAINST CD127

Office Singapore
Application Number 11201610036P
Application Date 10.06.2015
Publication Number 11201610036P
Publication Date 29.12.2016
Publication Kind A1
IPC
C CHEMISTRY; METALLURGY
07
ORGANIC CHEMISTRY
K
PEPTIDES
16
Immunoglobulins, e.g. monoclonal or polyclonal antibodies
18
against material from animals or humans
28
against receptors, cell surface antigens or cell surface determinants
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
K
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39
Medicinal preparations containing antigens or antibodies
C07K 16/28
A61K 39/00
CPC
A61K 2039/505
C07K 16/2866
C07K 2317/24
C07K 2317/34
C07K 2317/732
C07K 2317/76
Applicants OSE IMMUNOTHERAPEUTICS
Inventors Nicolas Poirier
Caroline Mary
Bernard Vanhove
Priority Data 15305078.6 23.01.2015 EP
62/010,117 10.06.2014 US
Title
(EN) ANTIBODIES DIRECTED AGAINST CD127
Abstract
(EN)
(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (43) International Publication Date 17 December 2015 (17.12.2015) WIPOIPCT (10) International Publication Number WO 2015/189302 A1 (51) International Patent Classification: C07K16/28 (2006.01) A61K39/00 (2006.01) (21) International Application Number: (22) International Filing Date: (25) Filing Language: (26) Publication Language: PCT/EP2015/062993 10 June 2015 (10.06.2015) English English (30) Priority Data: 62/010,117 15305078.6 10 June 2014 (10.06.2014) US 23 January 2015 (23.01.2015) EP (71) Applicant: EFFIMUNE [FR/FR]; 1, rue Gaston Veil, F- 44035 Nantes (FR). (72) Inventors: POIRIER, Nicolas; 1, chemin du Passe- Temps, F-44119 Treillieres (FR). MARY, Caroline; 7, rue du Buisson, F-44680 Sainte-Pazanne (FR). VANHOVE, Bernard; 72, bis Rue Henri Barbusse, F-44400 Reze (FR). (74) Agents: GUTMANN, Ernest et al.; 3, rue Auber, F-75009 Paris (FR). (81) Designated States (unless otherwise indicated, for every kind of national protection available)'. AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (84) Designated States (unless otherwise indicated, for every kind of regional protection available)'. ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). Published: — with international search report (Art. 21(3)) — with sequence listing part of description (Rule 5.2(a)) CJ o m o\ 00 i-H i?) T-H o CJ o & (54) Title: ANTIBODIES DIRECTED AGAINST CD 127 (57) Abstract: The invention relates to antibodies directed against CD 127, the alpha chain of the interleukin 7 (IL-7) receptor IL- 7R), and which have antagonist properties for IL-7-IL-7R interaction, may present cytotoxic activity against CD127 positive cells but do not increase the maturation of dendritic cells (DCs) induced by TSLP, a cytokine also using CD127 as part of its receptor. Al­ ternatively, or in addition, these antibodies do not induce the internalization of CD127 and/or inhibit the IL7-induced internalization of CD127. According to another aspect of the invention antibodies are provided which recognize a human CD127 epitope compris - ing sequences from the 2b site of CD 127, in particular the epitope comprising comprises the human CD 127 sequences of domain D1 and of the 2b site of CD127, in particular the epitope comprises at least one sequence from D1 comprising SEQ ID No: 115 (in par­ ticular comprising SEQ ID No: 10) and/or SEQ ID No: 111 and / or a sequence from the 2b site comprising the sequence of SEQ ID No: 116 and optionally also comprises SEQ ID No: 117 (in particular comprises SEQ ID No: 11 l).The antibodies of the invention are suitable for use inorder to remedy to a condition diagnosed in a human patient which results from pathogenesis related to lymph­ opoiesis, when IL-7 signalling pathways provide contribution to said pathogenesis, especially when an increase in the maturation, more precisely the upregulation of costimulatory molecules, of dendritic cells is undesirable.